Skip to Content
Merck
CN

Key Documents

View All Documentation

317496

BCI

≥95% (HPLC), Dusp1/CL100/HVH1/MKP1/PTPN10/Dusp6/MKP3/PYST1 Inhibitor, solid

Synonym(s):

Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI, NSC 150117, (E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one, MAP Kinase Phosphatase 1/3 Inhibitor, BCI, Dusp1/MKP1 Inhibitor, Dusp6/MKP3 Inhibitor, PTP Inhibitor XXVI

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C22H23NO
CAS Number:
15982-84-0
Molecular Weight:
317.42
MDL number:
MFCD20232928
UNSPSC Code:
12352204
NACRES:
NA.32
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI, The Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI controls the biological activity of Dual Specificity Protein Phosphatase 1/6. Primarily used for Phosphorylation & Dephosphorylation apps.

Quality Level

100

assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

yellow

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

2-8°C

SMILES string

N(C4CCCCC4)C1c2c(cccc2)C(=O)\C\1=C/c3ccccc3

InChI

1S/C22H23NO/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2/b20-15-

InChI key

XJDKPLZUXCIMIS-HKWRFOASSA-N

General description

A cell-permeable cyclohexylamino-indenone compound that acts as an allosteric inhibitor against substrate binding-induced MAPK phosphatase activity of Dusp1/CL100/HVH1/MKP1/PTPN10 and Dusp6/MKP3/PYST1 (57% and 30% reduction, respectively, of 0.21 and 2.1 µg Erk2-induced OMFP dephosphorylation by 0.21 µg Dusp6) by locking Dusp1 and Dusp6 in their low-activity conformation, while exhibiting little activity toward Cdc25B, DUSP3/VHR, DUSP5, or PTP1B. Shown to effectively enhance cellular Erk phosphorylation in HeLa cells overexpressing human Dusp1 and Dusp6 (EC50 = 11.5 and 12.3 µM, respectively). FGF signaling activation by BCI treatment (5 to 10 µM) during zebrafish embryo development is reported to expand myocardial progenitors population at the expense of other progenitor cell types, resulting in enlarged heart size.

Packaging

Packaged under inert gas

Preparation Note

Following reconstiution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Molina, G., et al. 2009. Nat. Chem. Biol.5, 680.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class

11 - Combustible Solids

wgk

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sabrina Blumer et al.
Cells, 10(11) (2021-11-28)
Idiopathic pulmonary fibrosis (IPF) is a progressive terminal lung disease, and therapies aim to block fibrosis. Fibroblast proliferation is controlled by C/EBP-β, microRNA cluster 17-92 (miR17-92), and Erk1/2 mitogen-activated protein kinase. This study assessed the role of miR17-92 in IPF-fibroblast
Briana C Prager et al.
Cancer discovery, 10(11), 1722-1741 (2020-07-25)
Meningiomas are the most common primary intracranial tumor with current classification offering limited therapeutic guidance. Here, we interrogated meningioma enhancer landscapes from 33 tumors to stratify patients based upon prognosis and identify novel meningioma-specific dependencies. Enhancers robustly stratified meningiomas into

Global Trade Item Number

SKUGTIN
317496-10MG04055977216226